0HB0 logo

Agios Pharmaceuticals LSE:0HB0 Stock Report

Last Price

US$32.08

Market Cap

US$1.9b

7D

-5.3%

1Y

2.1%

Updated

10 Mar, 2025

Data

Company Financials +

Agios Pharmaceuticals, Inc.

LSE:0HB0 Stock Report

Market Cap: US$1.9b

0HB0 Stock Overview

A biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. More details

0HB0 fundamental analysis
Snowflake Score
Valuation5/6
Future Growth2/6
Past Performance3/6
Financial Health6/6
Dividends0/6

Rewards

Trading at 94.4% below our estimate of its fair value

Revenue is forecast to grow 47.94% per year

Became profitable this year

Trading at good value compared to peers and industry

Risk Analysis

Earnings are forecast to decline by an average of 23.8% per year for the next 3 years

High level of non-cash earnings

Volatile share price over the past 3 months compared to the UK market


Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

My Notes

Capture your thoughts, links and company narrative

Agios Pharmaceuticals, Inc. Competitors

Bioventix

AIM:BVXP

UK£145.6m

PeptiDream

TSE:4587

JP¥262.5b

Sinocelltech Group

SHSE:688520

CN¥17.9b

Shanghai Henlius Biotech

SEHK:2696

HK$16.3b

Price History & Performance

Summary of share price highs, lows and changes for Agios Pharmaceuticals
Historical stock prices
Current Share PriceUS$32.08
52 Week HighUS$62.60
52 Week LowUS$27.37
Beta0.90
1 Month Change-4.39%
3 Month Change-30.04%
1 Year Change2.07%
3 Year Change7.03%
5 Year Change-40.55%
Change since IPO-60.26%

Recent News & Updates

Recent updates

Shareholder Returns

0HB0GB BiotechsGB Market
7D-5.3%-1.1%-2.7%
1Y2.1%-12.1%8.8%

Return vs Industry: 0HB0 exceeded the UK Biotechs industry which returned -11.5% over the past year.

Return vs Market: 0HB0 underperformed the UK Market which returned 9.6% over the past year.

Price Volatility

Is 0HB0's price volatile compared to industry and market?
0HB0 volatility
0HB0 Average Weekly Movement8.1%
Biotechs Industry Average Movement7.8%
Market Average Movement4.8%
10% most volatile stocks in GB Market10.2%
10% least volatile stocks in GB Market2.7%

Stable Share Price: 0HB0's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: 0HB0's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
2007487Brian Goffwww.agios.com

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company’s PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia.

Agios Pharmaceuticals, Inc. Fundamentals Summary

How do Agios Pharmaceuticals's earnings and revenue compare to its market cap?
0HB0 fundamental statistics
Market capUS$1.86b
Earnings (TTM)US$673.73m
Revenue (TTM)US$36.50m

2.7x

P/E Ratio

50.2x

P/S Ratio

Is 0HB0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0HB0 income statement (TTM)
RevenueUS$36.50m
Cost of RevenueUS$305.45m
Gross Profit-US$268.95m
Other Expenses-US$942.68m
EarningsUS$673.73m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)11.76
Gross Margin-736.90%
Net Profit Margin1,845.92%
Debt/Equity Ratio0%

How did 0HB0 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/10 23:53
End of Day Share Price 2025/03/10 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Agios Pharmaceuticals, Inc. is covered by 30 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
George FarmerBMO Capital Markets Equity Research
Alec StranahanBofA Global Research